Log in or Sign up for Free to view tailored content for your specialty!
Gastrointestinal Cancer News
FDA news: License applications accepted for melanoma, endometrial cancer therapies
The FDA announced several regulatory actions the past few weeks.
Immunomodulators heighten risk for high-grade cervical neoplasia, cancer in women with IBD
Cumulative exposure to immunomodulators increased the risk for high-grade cervical intraepithelial neoplasia and cervical cancer in women with inflammatory bowel disease, according to data from Alimentary Pharmacology & Therapeutics.
Log in or Sign up for Free to view tailored content for your specialty!
Novel AhR inhibitor shows tolerability, activity in advanced solid tumors
CHICAGO — A novel oral aryl hydrocarbon receptor inhibitor appeared well tolerated and safe among a small cohort of patients with advanced solid tumors, according to phase 1 study results presented at ASCO Annual Meeting.
NALIRIFOX extends OS, PFS for certain patients with pancreatic cancer
CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a study presented at ASCO Annual Meeting.
Tumor mutational burden associated with survival on immunotherapy across cancer types
CHICAGO — Higher tumor mutational burden appeared associated with more favorable real-world OS among a large cohort of patients with various cancer types who used immune checkpoint inhibitor monotherapy.
Hormone replacement therapy increases risk for GI cancers in postmenopausal women
CHICAGO — The odds of having gastric and pancreatic cancers were higher among postmenopausal women on hormone replacement therapy and remained significant after controlling for risk factors, according to data at Digestive Disease Week.
Trastuzumab deruxtecan shows ‘broad activity’ in HER2-expressing solid tumors
CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.
Neoadjuvant chemotherapy regimen shows durable survival benefit in rectal cancer
CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.
Some patients with locally advanced rectal cancer can be spared pelvic radiation
CHICAGO — Most patients with intermediate-risk rectal cancer can undergo curative-intent treatment without the need for pelvic radiation, according to study results presented during a press conference at ASCO Annual Meeting.
Healio | HemOncToday announce 2023 Disruptive Innovators at ASCO
CHICAGO — During ASCO Annual Meeting, Healio honored our Healio Disruptive Innovators in hematology/oncology in our second annual award ceremony.
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read